Lundbeck poaches CEO from Wyeth ranks

Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president of Wyeth's operations in Europe, the Middle East, African and Canada, Wiinberg also had been charged with strategic oversight of Wyeth's biopharma. Can Wiinberg deliver for Lundbeck? No doubt we'll soon see what he can do.

- read Lundbeck's release
- check out the brief at Money AM
- see the item at PharmaGossip

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.